BioSpace News Archive

Agenus Inc. (NASDAQ: AGEN),announced the dosing of the first COVID-19 patient with agenT-797, an allogeneic cell therapy, through its subsidiary, AgenTus Therapeutics.

Almost everyone knows someone impacted by diabetes. With over 122 million people in the U.S. living with diabetes or prediabetes, you don’t need to look too far outside your circle.

AIM ImmunoTech Inc. (NYSE American: AIM) announced today the publication of statistically significant data detailing how its drug Ampligen could have a considerable positive impact on people living with the debilitating illness myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) when administered in the early stages of the disease. The data were published in PLOS ONE , a peer-reviewed open access scientific journal published by the Publ

In Phase 2b study of patients with plaque psoriasis, roflumilast cream demonstrated rapid and clinically significant reduction in the severity and burden of itch and itch-related sleep loss as well as rapid improvement in patient-reported symptom burden Phase 2 proof-of-concept study in atopic dermatitis underscores potential of roflumilast cream as once-daily treatment for this common condition Roflumilast cream was safe and well-tolerated by psoriasis and atopic dermatitis patients in both P

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that at its special meeting of stockholders held on November 2, 2020, Rexahn’s stockholders approved all of the proposals presented, including: (i) the issuance of shares of Rexahn common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated June 17, 2020, as amended, by and among Rexahn, Razor Merger Sub, Inc. and Ocuphire Pharma, Inc. (“Ocuphire”) and

Klone 4.0 accomplishes both in a manner that could potentially disrupt the bioprocessing industry, firstly by reducing development times by up to 80% as AI eliminates many of the laboratory pain points through GBB’s proprietary deep machine learning techniques and algorithms and then by locating those cells with the highest expression c

aNew Orders; Production and Employment Growing; Supplier Deliveries Slowing at Faster Rate; Backlog Growing; Raw Materials Inventories Growing; Customers’ Inventories Too Low; Prices Increasing; Exports and Imports Growing

PPD, Inc. (Nasdaq: PPD ), was named the Clinical Research Company of the Year for winning multiple awards at the PharmaTimes Clinical Researcher of the Year competitions. In addition to PPD winning the highest honor at the PharmaTimes International Clinical Researcher of the Year 2020 virtual awards ceremony, individual PPD clinical researchers won gold and bronze in both the Clinical Research Associate (CRA) and

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a strategic collaboration with Janssen Research & Development, LLC (Janssen), in which Tempus will work closely with Janssen data scientists and oncologists focused on oncology clinical development programs. The collaboration is part of a multi-year data agreement, which is facilitating predictive AI/machine learning projects, as well as

Pancreatic cancer cells avert starvation by signaling to nerves, which grow into dense tumors and secrete nutrients.